button bars forest bayes pooled summary circles
 
deaths (OS)progression or deaths (PFS)RFS/DFS

mUC - L1 - all population metastatic/advanced UC (mUC) - 1st Line (L1) mUC - L1 - all population

versus gemcitabine plus platin
atezolizumab alone vs. gemcitabine plus platin 1 certainty unassessable+2%--
durvalumab alone vs. gemcitabine plus platin 1 certainty unassessable-1% certainty unassessable-21%-
durvalumab plus tremelimumab vs. gemcitabine plus platin 1 certainty unassessable-14% certainty unassessable+23%-
pembrolizumab plus SoC vs. gemcitabine plus platin 1 certainty unassessable-13% certainty unassessable-20%-
versus placebo plus SoC
atezolizumab plus SoC vs. placebo plus SoC 1 certainty unassessable-16% certainty unassessablestatistically conclusive-17%-
versus Standard of Care (SoC)
pembrolizumab alone vs. Standard of Care (SoC) 1 certainty unassessable-7% certainty unassessable+35%-

mUC - L1 - PDL1 positive metastatic/advanced UC (mUC) - 1st Line (L1) mUC - L1 - PDL1 positive

versus gemcitabine plus platin
durvalumab alone vs. gemcitabine plus platin 1 certainty unassessable-10% certainty unassessable+24%-
durvalumab plus tremelimumab vs. gemcitabine plus platin 1 certainty unassessable-24% certainty unassessable+2%-

mUC - L2 - all population metastatic/advanced UC (mUC) - 2nd Line (L2) mUC - L2 - all population

versus Standard of Care (SoC)
atezolizumab alone vs. Standard of Care (SoC) 1 certainty unassessable-14% certainty unassessable-10%-
pembrolizumab alone vs. Standard of Care (SoC) 1 certainty unassessablestatistically conclusive-25% certainty unassessable-2%-

mUC - L2 - PDL1 positive metastatic/advanced UC (mUC) - 2nd Line (L2) mUC - L2 - PDL1 positive

versus Standard of Care (SoC)
atezolizumab alone vs. Standard of Care (SoC) 2 certainty unassessable-12% certainty unassessable-13%-
pembrolizumab alone vs. Standard of Care (SoC) 1 certainty unassessablestatistically conclusive-40% certainty unassessable-10%-

mUC - M - all population metastatic/advanced UC (mUC) - maintenance (M) mUC - M - all population

versus BSC
avelumab alone vs. BSC 1 certainty unassessablestatistically conclusive-29% certainty unassessable-35%-

mUC - M - PDL1 positive metastatic/advanced UC (mUC) - maintenance (M) mUC - M - PDL1 positive

versus BSC
avelumab alone vs. BSC 1 certainty unassessablestatistically conclusive-40% certainty unassessable-40%-

MIBC - NA - all population muscular invasive bladder cancer (MIBC) MIBC - (neo)adjuvant (NA) MIBC - NA - all population

versus no additional treatment
atezolizumab alone vs. no additional treatment 1 ---
versus placebo
nivolumab alone vs. placebo 1 -- certainty unassessable-26%

MIBC - NA - PDL1 positive muscular invasive bladder cancer (MIBC) MIBC - (neo)adjuvant (NA) MIBC - NA - PDL1 positive

versus placebo
nivolumab alone vs. placebo 1 -- certainty unassessable-41%

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons